Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA61I2)

• Drug Name: 5,7-dihydroxy-3-phenyl-3H-quinazolin-4-one Drug Info
• Synonyms: 3-arylquinazolinone, 1au; CHEMBL378572; BDBM19929

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 11579722
  TTD Drug ID: DMA61I2

Molecule-Related Drug Atlas

Drug(s) Targeting Estrogen receptor beta (ESR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Conjugated Estrogens	DMLT0E1	Dyspareunia	GA12	Approved	[2]
Trilostane	DMQZ9GF	Cushing disease	5A70	Approved	[3]
ARZOXIFENE	DMOKCVI	Breast cancer	2C60-2C65	Approved	[4]
Estrogen	DMGY0UT	Menopause symptom	GA30.0	Approved	[5]
MF-101	DM8Z0I3	Hepatitis virus infection	1E50-1E51	Phase 3	[6]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[7]
AUS-131	DMUXO3Z	Hot flushes	GA30	Phase 2	[8]
ERB-041	DMCEPUA	Inflammatory bowel disease	DD72	Phase 2	[9]
Erteberel	DMU1XZD	Prostate hyperplasia	GA90	Phase 2	[10]
VG-101	DMAN21O	Menopause symptom	GA30.0	Phase 1/2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Estrogen receptor beta (ESR2)	TTOM3J0	ESR2_HUMAN	Inhibitor	[1]

References

• [1] Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators. J Med Chem. 2006 Apr 20;49(8):2440-55.
• [2] Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol. 2009 Jan;23(1):74-85.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007 May 31;50(11):2682-92.
• [5] Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15133-6.
• [6] MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause. 2009 May-Jun;16(3):458-65.
• [7] Company report (Axcentua)
• [8] S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9.
• [9] Erb-041, an estrogen receptor-beta agonist, inhibits skin photocarcinogenesis in SKH-1 hairless mice by downregulating the WNT signaling pathway. Cancer Prev Res (Phila). 2014 Feb;7(2):186-98.
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031986)
• [11] Update on alternative therapies for vulvovaginal atrophy. Patient Prefer Adherence. 2011; 5: 533-536.